Evidence-based guide to Mounjaro (tirzepatide) dosing for adults aged 50-64. Covers titration schedule, dose adjustments for kidney function and polypharmacy, and clinical trial data from SURPASS trials.
Evidence-based guide to tirzepatide (Mounjaro) safety during pregnancy and breastfeeding, including FDA labeling, animal data, washout timing, and what remains unknown.
Mounjaro is FDA-approved (May 2022) for type 2 diabetes, plus approved by EMA, MHRA, and Health Canada. See exact approval dates by country.
A clinician-grade review of tirzepatide (Mounjaro) safety signals, FDA black box warnings, postmarket adverse events, label revisions, and what prescribers should monitor.
Evidence-based guide to using Mounjaro (tirzepatide) in special populations including transplant recipients, people living with HIV, older adults, and patients with renal or hepatic impairment.
TRICARE covers Mounjaro (tirzepatide) for type 2 diabetes with prior authorization. Learn formulary tier placement, step therapy requirements, appeal steps for denials, and out-of-pocket cost options for military beneficiaries.
A clinical evidence summary of tirzepatide (Mounjaro) for heart failure, including SURMOUNT-HFpEF trial data, mechanism of action, current FDA-approved indications, and what the research means for patients with HFpEF.
Can Mounjaro (tirzepatide) be used for heart failure? Review the clinical trial data, off-label status, monitoring requirements, and what cardiologists recommend for HFpEF patients.
Tirzepatide (Mounjaro) is prescribed off-label for PCOS. Review the dosing protocol, clinical evidence for insulin resistance and ovulation, FDA status, and what the research actually shows.
Tirzepatide (Mounjaro) is not FDA-approved for PCOS, but emerging trial data suggest meaningful improvements in ovulation, insulin resistance, and androgen levels. Here is what clinicians and patients should know about the risks and tradeoffs.
Tirzepatide (Mounjaro) is being used off-label for obstructive sleep apnea. Review the SURMOUNT-OSA trial data, dosing protocols, AHI reductions, and what clinicians should know before prescribing.
A clinical evidence summary of tirzepatide (Mounjaro) used off-label for weight loss, including trial data from SURMOUNT and SURPASS, dosing, safety, and how it compares to semaglutide.
Semaglutide (Ozempic) 0.5-2.0 mg is being explored off-label for heart failure. Review the dosing protocol, trial evidence from SELECT and STEP-HFpEF, FDA-approved indications, and what clinicians should know.
Semaglutide (Ozempic) is not FDA-approved for heart failure, but emerging trial data in HFpEF shows measurable benefits. Learn the evidence, monitoring protocols, and safety considerations for off-label use.
Semaglutide (Ozempic) 0.5-2.0 mg is being studied for kidney protection in CKD. Review the off-label evidence, dosing protocols, FLOW trial results, and clinical guidance for renal use.
Semaglutide (Ozempic) 0.5 to 2.0 mg is used off-label for NASH. Review the dosing protocol, key trial data, FDA status, and what clinicians should know before prescribing.
Semaglutide (Ozempic) is not FDA-approved for NASH/MASH, but clinical trial data shows histological improvement in liver fibrosis and steatohepatitis. Learn the risks, dosing, and evidence.
Semaglutide (Ozempic) is used off-label for PCOS to improve insulin resistance, restore ovulation, and reduce androgen levels. Learn the dosing protocol, evidence base, and what clinicians should discuss with patients.
A evidence summary of off-label semaglutide (Ozempic) for polycystic ovary syndrome (PCOS), covering trial data on weight, androgens, ovulation, and insulin resistance.
Ozempic (semaglutide 0.5-2.0 mg) is FDA-approved for type 2 diabetes, not weight loss. Here's what the clinical trials show about off-label use, real risks, and how it compares to the approved weight-loss dose.
Can semaglutide 2.4 mg (Wegovy) treat alcohol use disorder? Review the preclinical and early clinical evidence, proposed dosing protocols, and what physicians should know before prescribing off-label.
Semaglutide 2.4 mg (Wegovy) is being used off-label for binge eating disorder. Review the clinical evidence, monitoring protocols, and what patients and clinicians should track during treatment.
A clinical review of semaglutide 2.4 mg (Wegovy) used off-label for binge eating disorder, including trial data, risk-benefit analysis, and practical prescribing considerations.
A clinical evidence review of semaglutide 2.4 mg (Wegovy) for nonalcoholic steatohepatitis (NASH/MASH), covering phase 2 and phase 3 trial data, mechanism of action, GRADE-level assessment, and practical prescribing considerations.
Semaglutide 2.4 mg (Wegovy) is used off-label for NASH/MASH. Learn the clinical trial evidence, monitoring schedule, liver enzyme targets, and what your provider should track.
Zepbound (tirzepatide) is FDA-approved for weight management, not diabetes. Learn about its off-label use for type 2 diabetes, the clinical evidence from SURPASS trials, and the monitoring your clinician should follow.
Zepbound (tirzepatide) is FDA-approved for weight management, not diabetes. Learn the evidence behind off-label use for type 2 diabetes, how it compares to Mounjaro, risks, and what clinicians consider before prescribing.
A clinical evidence review of tirzepatide (Zepbound) for heart failure, covering trial data from SUMMIT and STEP-HFpEF, FDA-approved indications, and what the research shows about cardiac outcomes.
Tirzepatide (Zepbound) is not FDA-approved for heart failure. Trial evidence in HFpEF with obesity shows symptom and functional improvement, but not proven reductions in hospitalization or death. Here is what the evidence supports, what remains unproven, and what monitoring off-label use requires.
Can Zepbound (tirzepatide) treat heart failure? Review the off-label evidence from SURMOUNT-HFpEF trials, FDA-approved indications, cardiovascular risks, and what clinicians consider before prescribing.
Tirzepatide (Zepbound) is not FDA-approved for PCOS, but clinicians are using it off-label based on its weight-loss and insulin-sensitizing effects. Here is what is established, what is plausible but unproven, and what monitoring is reasonable before and during treatment.
Complete Ozempic dosing guide for adults aged 30 to 49, covering the FDA-approved titration schedule, maintenance doses of 0.5 mg to 2.0 mg, missed-dose rules, and clinical trial outcomes from SUSTAIN and STEP programs.
Anthem (Elevance Health) covers Ozempic for type 2 diabetes with prior authorization and step therapy. Learn formulary tier placement, PA criteria, appeal options, and how to reduce out-of-pocket costs.
Complete guide to BCBS Federated coverage for Ozempic (semaglutide), including prior authorization criteria, formulary tier placement, step therapy requirements, appeal strategies, and cost-saving options.
Ozempic's 2023 list price is $935.77/month, close to Trulicity and Rybelsus but under Mounjaro. Compare costs and weight-loss results before switching.
A clinical review of Novo Nordisk's semaglutide pipeline, including oral semaglutide upgrades, CagriSema, amycretin, and next-generation GLP-1 receptor agonists in development beyond current Ozempic formulations.
Evidence-based monitoring guide for semaglutide (Ozempic) in adults 65 and older, covering renal function, sarcopenia screening, fall risk, polypharmacy review, and dose titration.
Evidence-based safety profile of Ozempic (semaglutide 0.5-2.0 mg) in adults aged 65 and older, including fall risk, renal considerations, muscle loss, and monitoring protocols.
Evidence-based guide to semaglutide (Ozempic) dosing in patients with hepatic impairment, including pharmacokinetic data, clinical trial evidence, and monitoring recommendations.
A physician-level breakdown of how Ozempic (semaglutide) works, from GLP-1 receptor binding and cAMP signaling to beta-cell insulin secretion, appetite suppression, and gastric slowing.
Find out whether Medicare Advantage plans cover Ozempic (semaglutide) for type 2 diabetes or weight loss, including formulary placement, prior-authorization criteria, step therapy, and how to appeal a denial.
A clinical review of semaglutide (Ozempic) safety in adults aged 50-64, covering cardiovascular data, GI tolerability, muscle preservation, polypharmacy risks, and monitoring guidelines.
A clinical breakdown of Novo Nordisk's semaglutide patent portfolio, key expiration dates, Paragraph IV challenges, and the realistic timeline for generic Ozempic approval.
Why some patients lose 15% body weight on Ozempic while others plateau at 3%. A deep look at GLP1R, TCF7L2, and other gene variants that influence semaglutide efficacy, side effects, and dosing.
FDA labeling, animal data, and clinical guidance on semaglutide use before conception, during pregnancy, and while breastfeeding. Includes washout timelines and alternative glucose-management options.
The FDA added ileus to the Ozempic label in September 2023 based on FAERS postmarketing reports; intestinal obstruction was added earlier in June 2020.
How to store Ozempic (semaglutide) pens before and after first use, what happens if Ozempic is left unrefrigerated, and how long opened pens last. FDA-cited.
Complete guide to Ozempic (semaglutide) dosing for young adults aged 18 to 29, covering escalation schedules, fertility considerations, side effects, and off-label weight management.
A clinical review of semaglutide (Ozempic) safety data relevant to adults aged 18 to 29, covering side effects, fertility, cardiovascular outcomes, and monitoring recommendations.
Mounjaro EMA product information: tirzepatide was authorised EU-wide on 15 September 2022, and the SmPC now covers type 2 diabetes and weight management.
Every FDA label change for Mounjaro (tirzepatide) from initial approval through 2026, including new indications, boxed warnings, safety communications, and post-market requirements.
A guide to the legal status of compounded semaglutide (Ozempic), FDA shortage declarations, 503A/503B pharmacy rules, and what changes mean for patients in 2026.
A clinical comparison of how the FDA and EMA regulate Ozempic (semaglutide), covering approval timelines, label differences, boxed warnings, post-market surveillance, and safety monitoring frameworks.
Every FDA label change to Ozempic (semaglutide 0.5-2.0 mg) from 2020 through 2026, including new warnings, dose expansions, and post-market safety signals.
A clinical review of Rybelsus (oral semaglutide) regulatory history, current FDA label, post-market safety data, and Novo Nordisk's next-generation oral GLP-1 pipeline.
Wegovy (semaglutide 2.4 mg) prescribing information: FDA approved June 4, 2021; EMA authorized January 6, 2022; cardiovascular indication added March 2024.
A clinical review of the Wegovy regulatory timeline, current label, post-market safety data, and the next-generation GLP-1 and multi-agonist drugs in development that may succeed semaglutide 2.4 mg.
An evidence-based review of Wegovy (semaglutide 2.4 mg) safety signals reported to the FDA Adverse Event Reporting System (FAERS), including GI events, pancreatitis, thyroid neoplasms, and gallbladder disorders.
A detailed breakdown of the legal, patent, and regulatory challenges facing Zepbound (tirzepatide), including FDA approval history, compounding pharmacy litigation, patent exclusivity timelines, and post-market safety surveillance.
Real-world cost data for Ozempic (semaglutide) drawn from patient forums, insurance claims analyses, and manufacturer pricing. Includes coupon strategies, state-by-state variation, and how to lower your out-of-pocket spend.